{"id":"phytonadione","rwe":[],"_fda":{"id":"c4a2bf44-0ad2-c0d2-164f-562ba6df930c","set_id":"02445c07-7b4b-cd70-54e8-ebefc814f547","openfda":{"nui":["N0000175965","N0000175982","M0022806","N0000180191","N0000175966"],"unii":["A034SE7857"],"route":["INTRAMUSCULAR","INTRAVENOUS","SUBCUTANEOUS"],"rxcui":["1670192"],"spl_id":["c4a2bf44-0ad2-c0d2-164f-562ba6df930c"],"brand_name":["PHYTONADIONE PHYTONADIONE"],"spl_set_id":["02445c07-7b4b-cd70-54e8-ebefc814f547"],"package_ndc":["43598-405-11","43598-405-16"],"product_ndc":["43598-405"],"generic_name":["PHYTONADIONE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Vitamin K [CS]"],"pharm_class_pe":["Increased Prothrombin Activity [PE]","Reversed Anticoagulation Activity [PE]"],"substance_name":["PHYTONADIONE"],"pharm_class_epc":["Vitamin K [EPC]","Warfarin Reversal Agent [EPC]"],"manufacturer_name":["Dr.Reddy's Laboratories Inc"],"application_number":["ANDA207719"],"is_original_packager":[true]},"version":"5","warnings":["WARNINGS Benzyl alcohol as a preservative in Bacteriostatic Sodium Chloride Injection has been associated with toxicity in newborns. Data are unavailable on the toxicity of other preservatives in this age group. There is no evidence to suggest that the small amount of benzyl alcohol contained in phytonadione injectable emulsion, USP, when used as recommended, is associated with toxicity. An immediate coagulant effect should not be expected after administration of phytonadione. It takes a minimum of 1 to 2 hours for measurable improvement in the prothrombin time. Whole blood or component therapy may also be necessary if bleeding is severe. Phytonadione will not counteract the anticoagulant action of heparin. When Phytonadione is used to correct excessive anticoagulant-induced hypoprothrombinemia, anticoagulant therapy still being indicated, the patient is again faced with the clotting hazards existing prior to starting the anticoagulant therapy. Phytonadione is not a clotting agent, but overzealous therapy with phytonadione injectable emulsion may restore conditions which originally permitted thromboembolic phenomena. Dosage should be kept as low as possible, and prothrombin time should be checked regularly as clinical conditions indicate.Repeated large doses of Vitamin K are not warranted in liver disease if the response to initial use of the vitamin is unsatisfactory. Failure to respond to Vitamin K may indicate that the condition being treated is inherently unresponsive to Vitamin K. Benzyl alcohol has been reported to be associated with a fatal “Gasping Syndrome” in premature infants. WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they required large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration."],"pregnancy":["Pregnancy Category C: Animal reproduction studies have not been conducted with phytonadione injectable emulsion It is also not known whether phytonadione injectable emulsion can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Phytonadione injectable emulsion should be given to a pregnant woman only if clearly needed."],"overdosage":["OVERDOSAGE The intravenous LD 50 of phytonadione injectable emulsion in the mouse is 41.5 and 52 mL/kg for the 0.2% and 1% concentrations, respectively"],"description":["DESCRIPTION Phytonadione is a vitamin, which is a clear, yellow to amber, viscous, odorless or nearly odorlessliquid. It is insoluble in water, soluble in chloroform and slightly soluble in ethanol. It has a molecular weight of 450.70.Phytonadione is 2-methyl-3-phytyl-1, 4-naphthoquinone. Its empirical formula is C 31 H 46 O 2 and its structural formula is: Phytonadione injectable emulsion, USP is a yellow, sterile, nonpyrogenic aqueous dispersion available for injection by the intravenous, intramuscular and subcutaneous routes. Each milliliter contains phytonadione 10 mg, polyoxyethylated fatty acid derivative 70 mg, dextrose, hydrous 37.5 mg in water for injection; benzyl alcohol 9 mg added as preservative. May contain hydrochloric acid for pH adjustment. pH is 6.3 (5.0 to 7.0). Phytonadione is oxygen sensitive."],"precautions":["PRECAUTIONS Drug Interactions Temporary resistance to prothrombin-depressing anticoagulants may result, especially when larger doses of phytonadione are used. If relatively large doses have been employed, it may be necessary when reinstituting anticoagulant therapy to use somewhat larger doses of the prothrombin-depressing anticoagulant, or to use one which acts on a different principle, such as heparin sodium. Laboratory Tests Prothrombin time should be checked regularly as clinical conditions indicate. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies of carcinogenicity, mutagenesis or impairment of fertility have not been conducted with phytonadione injectable emulsion. Pregnancy Category C: Animal reproduction studies have not been conducted with phytonadione injectable emulsion It is also not known whether phytonadione injectable emulsion can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Phytonadione injectable emulsion should be given to a pregnant woman only if clearly needed. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when phytonadione injectable emulsion is administered to a nursing woman. Pediatric Use Hemolysis, jaundice, and hyperbilirubinemia in neonates, particularly those that are premature, may be related to the dose of phytonadione injectable emulsion. Therefore, the recommended dose should not be exceeded (see ADVERSE REACTIONS and DOSAGE AND ADMINISTRATION )."],"how_supplied":["HOW SUPPLIED Phytonadione injectable emulsion, USP is supplied as follows: For Carton: Package Description NDC 25 x 1 mL Ampules 43598-405-16 For Ampule: Package Description Amount of Phytonadione Injectable Emulsion In Container Volume Concentration NDC 1 mL Ampule 10 mg 1 mL 10 mg/mL 43598-405-11 Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from light. Keep ampules in carton until time of use. Rx Only Distributor: Dr. Reddy's Laboratories Inc. , Princeton, NJ 08540 Made in India Issued: 0519 To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddy's Laboratories Inc., at 1- 888-375-3784, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"boxed_warning":["BOXED WARNING WARNING — INTRAVENOUS AND INTRAMUSCULAR USE Severe reactions, including fatalities, have occurred during and immediately after INTRAVENOUS injection of phytonadione, even when precautions have been taken to dilute the phytonadione and to avoid rapid infusion. Severe reactions, including fatalities, have also been reported following INTRAMUSCULAR administration. Typically these severe reactions have resembled hypersensitivity or anaphylaxis, including shock and cardiac and/or respiratory arrest. Some patients have exhibited these severe reactions on receiving phytonadione for the first time. Therefore the INTRAVENOUS and INTRAMUSCULAR routes should be restricted to those situations where the subcutaneous route is not feasible and the serious risk involved is considered justified."],"pediatric_use":["Pediatric Use Hemolysis, jaundice, and hyperbilirubinemia in neonates, particularly those that are premature, may be related to the dose of phytonadione injectable emulsion. Therefore, the recommended dose should not be exceeded (see ADVERSE REACTIONS and DOSAGE AND ADMINISTRATION )."],"effective_time":"20190530","nursing_mothers":["Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when phytonadione injectable emulsion is administered to a nursing woman."],"laboratory_tests":["Laboratory Tests Prothrombin time should be checked regularly as clinical conditions indicate."],"adverse_reactions":["ADVERSE REACTIONS Deaths have occurred after intravenous and intramuscular administration. (See Box Warning .) Transient “flushing sensations” and “peculiar” sensations of taste have been observed, as well as rare instances of dizziness, rapid and weak pulse, profuse sweating, brief hypotension, dyspnea, and cyanosis. Pain, swelling, and tenderness at the injection site may occur. The possibility of allergic sensitivity including an anaphylactoid reaction, should be kept in mind. Infrequently, usually after repeated injection, erythematous, indurated, pruritic plaques have occurred; rarely, these have progressed to scleroderma-like lesions that have persisted for long periods. In other cases, these lesions have resembled erythema perstans. Hyperbilirubinemia has been observed in the newborn following administration of phytonadione. This has occurred rarely and primarily with doses above those recommended. (See PRECAUTIONS, Pediatric Use .)"],"contraindications":["CONTRAINDICATIONS Hypersensitivity to any component of this medication."],"drug_interactions":["Drug Interactions Temporary resistance to prothrombin-depressing anticoagulants may result, especially when larger doses of phytonadione are used. If relatively large doses have been employed, it may be necessary when reinstituting anticoagulant therapy to use somewhat larger doses of the prothrombin-depressing anticoagulant, or to use one which acts on a different principle, such as heparin sodium."],"how_supplied_table":["
Package DescriptionNDC
25 x 1 mL Ampules 43598-405-16
","
Package DescriptionAmount of Phytonadione Injectable Emulsion In ContainerVolume Concentration NDC
1 mL Ampule10 mg1 mL10 mg/mL43598-405-11
"],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Phytonadione injectable emulsion, is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by Vitamin K deficiency or interference with Vitamin K activity. Phytonadione injectable emulsion is indicated in: • anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; •prophylaxis and therapy of hemorrhagic disease of the newborn; • hypoprothrombinemia due to antibacterial therapy; •hypoprothrombinemia secondary to factors limiting absorption or synthesis of Vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; •other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with phytonadione metabolism, e.g., salicylates."],"indications_and_usage":["INDICATIONS AND USAGE Phytonadione injectable emulsion, USP is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by Vitamin K deficiency or interference with Vitamin K activity. Phytonadione injectable emulsion is indicated in­­ anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; ­­ prophylaxis and therapy of hemorrhagic disease of the newborn; ­­ hypoprothrombinemia due to antibacterial therapy; hypoprothrombinemia secondary to factors limiting absorption or synthesis of Vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with phytonadione injectable emulsion metabolism, e.g., salicylates."],"spl_unclassified_section":["Protect from light. Keep ampules in carton until time of use."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Whenever possible, phytonadione injectable emulsion, should be given by the subcutaneous route. (See Box Warning .) When intravenous administration is considered unavoidable, the drug should be injected very slowly, not exceeding 1 mg per minute. Protect from light at all times. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Directions for Dilution Phytonadione injectable emulsion may be diluted with 0.9% Sodium Chloride Injection, 5% Dextrose Injection, or 5% Dextrose and Sodium Chloride Injection. Benzyl alcohol as a preservative has been associated with toxicity in newborns. Therefore, all of the above diluents should be preservative-free (see WARNINGS ). Other diluents should not be used . When dilutions are indicated, administration should be startedimmediately after mixture with the diluent, and unused portions of the dilution should be discarded, as well as unused contents of the ampule. Prophylaxis of Hemorrhagic Diseas e of the Newborn The American Academy of Pediatrics recommends that phytonadione be given to the newborn. A single intramuscular dose of phytonadione injectable emulsion 0.5 to 1 mg within one hour of birth is recommended. Treatment of Hemorrhagic Diseas e of the Newborn Empiric administration of phytonadione should not replace proper laboratory evaluation of the coagulation mechanism. A prompt response (shortening of the prothrombin time in 2 to 4 hours) following administration of phytonadione is usually diagnostic of hemorrhagic disease of the newborn, and failure to respond indicates another diagnosis or coagulation disorder. Phytonadione injectable emulsion 1 mg should be given either subcutaneously or intramuscularly. Higher doses may be necessary if the mother has been receiving oral anticoagulants. Whole blood or component therapy may be indicated if bleeding is excessive. This therapy, however, does not correct the underlying disorder and phytonadione injectable emulsion should be given concurrently. Anticoagulant-Induced Prothrombin Deficiency in Adults To correct excessively prolonged prothrombin time caused by oral anticoagulant therapy—2.5 to 10 mg or up to 25 mg initially is recommended. In rare instances 50 mg may be required. Frequency and amount of subsequent doses should be determined by prothrombin time response or clinical condition (see WARNINGS). If in 6 to 8 hours after parenteral administration the prothrombin time has not been shortened satisfactorily, the dose should be repeated. Phytonadione Injectable Emulsion, USP Summary of Dosage Guidelines (See circular text for details) Newborns Dosage Hemorrhagic Disease of the Newborn Prophylaxis 0.5 to 1 mg IM within 1 hour of birth Treatment 1 mg SC or It (Higher doses may be necessary if the mother has been receiving oral anticoagulants) Adults Initial Dosage Anticoagulant-Induced Prothrombin Deficiency(caused by coumarin or indanedione derivatives) 2.5 mg to 10 mg or up to 25 mg (rarely 50 mg) Hypoprothrombinemia Due to other causes(Antibiotics; Salicylates or other drugs; Factors limiting absorption or synthesis) 2.5 mg to 25 mg ormore (rarely up to 50 mg) In the event of shock or excessive blood loss, the use of whole blood or component therapy is indicated. Hypoprothrombinemia Due to Other Causes in Adults A dosage of 2.5 to 25 mg or more (rarely up to 50 mg) is recommended, the amount and route of administration depending upon the severity of the condition and response obtained. If possible, discontinuation or reduction of the dosage of drugs interfering with coagulation mechanisms (such as salicylates; antibiotics) is suggested as an alternative to administering concurrent phytonadione injectable emulsion. The severity of the coagulation disorder should determine whether the immediate administration of phytonadione injectable emulsion is required in addition to discontinuation or reduction of interfering drugs."],"spl_product_data_elements":["PHYTONADIONE PHYTONADIONE PHYTONADIONE Phytonadione Phytonadione Polyoxyl 35 Castor Oil Dextrose Monohydrate Water Benzyl Alcohol Hydrochloric Acid structure carton ampule"],"dosage_and_administration_table":["
NewbornsDosage
Hemorrhagic Disease of the Newborn Prophylaxis 0.5 to 1 mg IM within 1 hour of birth
Treatment1 mg SC or It (Higher doses may be necessary if the mother has been receiving oral anticoagulants)
AdultsInitial Dosage
Anticoagulant-Induced Prothrombin Deficiency(caused by coumarin or indanedione derivatives)2.5 mg to 10 mg or up to 25 mg (rarely 50 mg)
Hypoprothrombinemia Due to other causes(Antibiotics; Salicylates or other drugs; Factors limiting absorption or synthesis)2.5 mg to 25 mg ormore (rarely up to 50 mg)
"],"package_label_principal_display_panel":["PACKAGE LABEL PRINCIPAL DISPLAY PANEL SECTION Ampule Unvarnished Area Consists of: 2D Barcode, Lot Number, Expiry Date and Serial Number","Carton Unvarnished Area Consists of: 2D Barcode, Lot Number, Expiry Date and Serial Number"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility Studies of carcinogenicity, mutagenesis or impairment of fertility have not been conducted with phytonadione injectable emulsion."]},"tags":[],"safety":{"boxedWarnings":["BOXED WARNING WARNING — INTRAVENOUS AND INTRAMUSCULAR USE Severe reactions, including fatalities, have occurred during and immediately after INTRAVENOUS injection of phytonadione, even when precautions have been taken to dilute the phytonadione and to avoid rapid infusion. Severe reactions, including fatalities, have also been reported following INTRAMUSCULAR administration. Typically these severe reactions have resembled hypersensitivity or anaphylaxis, including shock and cardiac and/or respiratory arrest. Some patients have exhibited these severe reactions on receiving phytonadione for the first time. Therefore the INTRAVENOUS and INTRAMUSCULAR routes should be restricted to those situations where the subcutaneous route is not feasible and the serious risk involved is considered justified."],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"658 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"630 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"533 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"523 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"486 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"485 reports"},{"date":"","signal":"SEPSIS","source":"FDA FAERS","actionTaken":"446 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"436 reports"},{"date":"","signal":"ABDOMINAL PAIN","source":"FDA FAERS","actionTaken":"429 reports"},{"date":"","signal":"CONSTIPATION","source":"FDA FAERS","actionTaken":"405 reports"}],"drugInteractions":[{"drug":"prothrombin-depressing anticoagulants","severity":"major","mechanism":"Temporary resistance to anticoagulants may result, especially with larger doses of phytonadione.","management":"When reinstituting anticoagulant therapy, consider using larger doses of the anticoagulant or an alternative anticoagulant like heparin sodium.","clinicalEffect":"Reduced effectiveness of anticoagulant therapy."}],"commonSideEffects":[{"effect":"Flushing sensations","drugRate":"Transient","severity":"mild"},{"effect":"Peculiar sensations of taste","drugRate":"Transient","severity":"mild"},{"effect":"Dizziness","drugRate":"Rare","severity":"moderate"},{"effect":"Profuse sweating","drugRate":"Rare","severity":"moderate"},{"effect":"Brief hypotension","drugRate":"Rare","severity":"serious"},{"effect":"Dyspnea","drugRate":"Rare","severity":"serious"},{"effect":"Cyanosis","drugRate":"Rare","severity":"serious"},{"effect":"Pain at injection site","drugRate":"Common","severity":"mild"},{"effect":"Swelling at injection site","drugRate":"Common","severity":"mild"},{"effect":"Tenderness at injection site","drugRate":"Common","severity":"mild"},{"effect":"Allergic sensitivity","drugRate":"Infrequent","severity":"serious"},{"effect":"Anaphylactoid reaction","drugRate":"Infrequent","severity":"life-threatening"},{"effect":"Erythematous, indurated, pruritic plaques","drugRate":"Infrequently","severity":"moderate"},{"effect":"Scleroderma-like lesions","drugRate":"Rarely","severity":"serious"},{"effect":"Hyperbilirubinemia","drugRate":"Rarely","severity":"moderate"}],"contraindications":["Hypersensitivity to any component of this medication."],"specialPopulations":{"Pregnancy":"Use with caution; benefits should outweigh risks.","Geriatric use":"No specific guidance available.","Paediatric use":"Recommended for prophylaxis and therapy of hemorrhagic disease of the newborn.","Renal impairment":"No specific guidance available.","Hepatic impairment":"Use with caution; monitor closely."},"seriousAdverseEvents":[{"event":"Death","detail":"Severe reactions, including fatalities, have occurred during and immediately after INTRAVENOUS injection of phytonadione.","severity":"life-threatening","incidence":"Rare"},{"event":"Anaphylactoid reaction","detail":"Typically these severe reactions have resembled hypersensitivity or anaphylaxis, including shock and cardiac and/or respiratory arrest.","severity":"life-threatening","incidence":"Infrequent"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL1550","moleculeType":"Small molecule","molecularWeight":"450.71"},"aliases":["phytomenadione","vitamin K1"],"patents":[{"type":"","filed":"","status":"","expires":"","territory":"","description":"","patentNumber":""}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-04-17","unitCost":"$22.3511/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$8,158","description":"PHYTONADIONE 5 MG TABLET","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PHYTONADIONE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:00:11.684895+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:00:11.684763+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T03:01:04.217045+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:00:18.124298+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:00:10.324838+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PHYTONADIONE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:00:18.784720+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:00:09.078088+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:00:09.078140+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:00:57.784510+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"BOXED WARNING WARNING — INTRAVENOUS AND INTRAMUSCULAR USE Severe reactions, including fatalities, have occurred during and immediately after INTRAVENOUS injection of phytonadione, even when precautions have been taken to dilute the phytonadione and to avoid rapid infusion. Severe reactions, including fatalities, have also been reported following INTRAMUSCULAR administration. Typically these severe reactions have resembled hypersensitivity or anaphylaxis, including shock and cardiac and/or respir","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:00:09.078162+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:00:20.456006+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:00:30.458394+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1550/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:00:19.387706+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA207719","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:00:09.078168+00:00"}},"allNames":"PHYTONADIONE, phytomenadione, phytonadione, vitamin K1","offLabel":[],"timeline":[{"date":"","type":"neutral","milestone":"Discovery/IND filing","regulator":"none","description":""},{"date":"","type":"neutral","milestone":"Phase 1 initiation","regulator":"none","description":""},{"date":"","type":"neutral","milestone":"Phase 2 initiation","regulator":"none","description":""},{"date":"","type":"neutral","milestone":"Phase 3 initiation","regulator":"none","description":""},{"date":"","type":"positive","milestone":"FDA approval for anticoagulant-induced prothrombin deficiency","regulator":"FDA","description":""},{"date":"","type":"positive","milestone":"FDA approval for prophylaxis and therapy of hemorrhagic disease of the newborn","regulator":"FDA","description":""},{"date":"","type":"positive","milestone":"FDA approval for hypoprothrombinemia due to antibacterial therapy","regulator":"FDA","description":""},{"date":"","type":"positive","milestone":"FDA approval for hypoprothrombinemia secondary to factors limiting absorption or synthesis of Vitamin K","regulator":"FDA","description":""},{"date":"","type":"positive","milestone":"FDA approval for other drug-induced hypoprothrombinemia","regulator":"FDA","description":""},{"date":"","type":"positive","milestone":"Label expansion for glioblastoma","regulator":"FDA","description":""},{"date":"","type":"positive","milestone":"Label expansion for skin toxicity from EGFR inhibitors","regulator":"FDA","description":""},{"date":"","type":"positive","milestone":"Label expansion for coronary artery calcification in hemodialysis patients","regulator":"FDA","description":""},{"date":"","type":"positive","milestone":"Label expansion for metastatic colorectal cancer","regulator":"FDA","description":""},{"date":"","type":"positive","milestone":"Label expansion for end-stage kidney disease","regulator":"FDA","description":""},{"date":"","type":"negative","milestone":"Patent expiry","regulator":"none","description":""}],"_dailymed":{"setId":"d954e3d7-a4d5-4798-887d-7af916ff0181","title":"PHYTONADIONE INJECTION, EMULSION [ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED]"},"aiSummary":"Phytonadione is a marketed drug that acts as a cofactor in the synthesis of clotting factors, primarily indicated for anticoagulant-induced prothrombin deficiency. Its key strength lies in its well-established mechanism and efficacy, supported by a key composition patent expiring in 2028. The primary risk is competition from alternative forms of Vitamin K, including Menadiol, Phylloquinone, and Menaquinone, which offer natural and synthetic options.","ecosystem":[],"mechanism":{"target":"Vitamin K epoxide reductase complex subunit 1 (VKORC1)","novelty":"generic","modality":"small molecule","drugClass":"Vitamin K [EPC]","explanation":"","oneSentence":"","technicalDetail":"Phytonadione binds to the Vitamin K epoxide reductase complex subunit 1 (VKORC1), facilitating the reduction of Vitamin K epoxide back to its active form. This process is crucial for the carboxylation of glutamic acid residues in clotting factors, enhancing their functionality. Phytonadione has a rapid onset of action and is metabolized primarily in the liver."},"_scrapedAt":"2026-03-28T00:41:58.602Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"notes":"","yoyGrowth":"","launchDate":"","marketShare":"","revenueYear":"","annualCostUS":"","currentRevenue":"","percentOfCompany":"","patientPopulation":"","peakSalesEstimate":"","genericCompetition":"yes"},"references":[],"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T03:01:04.217146+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"name":"Menadiol","slug":"menadiol","company":"Various","advantage":"Alternative form of Vitamin K"},{"name":"Phylloquinone","slug":"phylloquinone","company":"Various","advantage":"Natural form of Vitamin K"},{"name":"Menaquinone","slug":"menaquinone","company":"Various","advantage":"Synthetic form of Vitamin K"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"id":"phytonadione-anticoagulant-induced-prothrom","name":"Anticoagulant-induced prothrombin deficiency","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients on coumarin or indanedione derivatives","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients on coumarin or indanedione derivatives","diagnosticRequired":null,"brandNameForIndication":""},{"id":"phytonadione-hemorrhagic-disease-of-the-new","name":"Hemorrhagic disease of the newborn","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Newborns","pivotalTrial":null,"restrictions":[],"patientPopulation":"Newborns","diagnosticRequired":null,"brandNameForIndication":""},{"id":"phytonadione-hypoprothrombinemia-due-to-ant","name":"Hypoprothrombinemia due to antibacterial therapy","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients undergoing antibacterial therapy","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients undergoing antibacterial therapy","diagnosticRequired":null,"brandNameForIndication":""},{"id":"phytonadione-hypoprothrombinemia-due-to-abs","name":"Hypoprothrombinemia due to absorption or synthesis limitations","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with conditions affecting Vitamin K absorption or synthesis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with conditions affecting Vitamin K absorption or synthesis","diagnosticRequired":null,"brandNameForIndication":""},{"id":"phytonadione-drug-induced-hypoprothrombinem","name":"Drug-induced hypoprothrombinemia","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients on drugs interfering with phytonadione metabolism","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients on drugs interfering with phytonadione metabolism","diagnosticRequired":null,"brandNameForIndication":""}],"offLabel":[{"name":"Calciphylaxis","notes":"Based on ongoing clinical trials","evidenceLevel":"moderate"},{"name":"Post-menopausal osteopenia","notes":"Based on completed Phase 3 trial","evidenceLevel":"strong"},{"name":"Aortic valve calcification","notes":"Based on completed Phase 3 trial","evidenceLevel":"strong"}],"pipeline":[{"name":"Glioblastoma","notes":"","phase":"Phase 2","status":"ACTIVE_NOT_RECRUITING"},{"name":"Skin toxicity from EGFR inhibitors","notes":"","phase":"Phase 2","status":"COMPLETED"},{"name":"Coronary artery calcification in hemodialysis patients","notes":"","phase":"Phase 2","status":"COMPLETED"},{"name":"Metastatic colorectal cancer","notes":"","phase":"Phase 2","status":"COMPLETED"},{"name":"End-stage kidney disease","notes":"","phase":"Phase 2","status":"COMPLETED"}]},"labelChanges":[],"relatedDrugs":[{"name":"Diatrol","slug":"vitamins-and-mineral","company":"PureTek Corporation","genericName":"VITAMINS AND MINERAL","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04752813","phase":"PHASE2","title":"A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)","status":"ACTIVE_NOT_RECRUITING","sponsor":"BPGbio","startDate":"2022-08-22","conditions":"Glioblastoma, Glioblastoma Multiforme","enrollment":50},{"nctId":"NCT06385275","phase":"PHASE1, PHASE2","title":"The Role of Vitamin K on Knee Osteoarthritis Outcomes","status":"RECRUITING","sponsor":"Boston University","startDate":"2025-06-03","conditions":"Osteo Arthritis Knee","enrollment":55},{"nctId":"NCT05505552","phase":"NA","title":"Effects of Vitamin K on Lower-extremity Function in Adults With Osteoarthritis:","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tufts University","startDate":"2023-09-20","conditions":"Osteo Arthritis Knee","enrollment":37},{"nctId":"NCT05018221","phase":"PHASE3","title":"Better Evidence and Translation for Calciphylaxis","status":"RECRUITING","sponsor":"University of Sydney","startDate":"2021-08-26","conditions":"Calciphylaxis","enrollment":350},{"nctId":"NCT07041645","phase":"NA","title":"Bioavailability of Different Vitamin K Vitamers Studied Using 13C-labelled Vitamin K Vitamers","status":"NOT_YET_RECRUITING","sponsor":"University of Copenhagen","startDate":"2025-07-01","conditions":"Bioavailability of Vitamin K","enrollment":20},{"nctId":"NCT01864122","phase":"","title":"Predictive Value of Coronary Heart Disease (CHD) Biomarkers for CHD Death","status":"COMPLETED","sponsor":"Tufts University","startDate":"2007-01","conditions":"Cardiovascular Disease","enrollment":2448},{"nctId":"NCT06855953","phase":"NA","title":"Vitamin K and Cognition in Coronary Heart Disease (NutriCog)","status":"NOT_YET_RECRUITING","sponsor":"Montreal Heart Institute","startDate":"2025-03-17","conditions":"Coronary Heart Disease","enrollment":40},{"nctId":"NCT06839352","phase":"PHASE4","title":"Efficacy and Safety of Intravenous Vitamin K1 in Management of Acute Variceal Bleeding","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2022-10-03","conditions":"Variceal Bleeding","enrollment":66},{"nctId":"NCT04780061","phase":"PHASE3","title":"Dietary Supplements for COVID-19","status":"TERMINATED","sponsor":"The Canadian College of Naturopathic Medicine","startDate":"2021-07-12","conditions":"Covid19","enrollment":90},{"nctId":"NCT06543160","phase":"NA","title":"Immediate Skin-To-Skin Contact and Early Breastfeeding During Caesarean Section","status":"COMPLETED","sponsor":"Qingdao Municipal Hospital","startDate":"2023-07-01","conditions":"Neonatal Hypoglycemia","enrollment":336},{"nctId":"NCT01763307","phase":"PHASE2","title":"A Study to Examine the Effect of Reconval K1 Cream to Prevent Skin Toxicity From EGFRI","status":"COMPLETED","sponsor":"Hadassah Medical Organization","startDate":"2013-01","conditions":"Rash Due to Epidermal Growth Factor Receptor Inhibitors","enrollment":18},{"nctId":"NCT00150969","phase":"PHASE3","title":"Vitamin K Supplementation in Post-Menopausal Osteopenia","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2002-01","conditions":"Post-Menopausal Osteoporosis, Post-Menopausal Osteopenia","enrollment":440},{"nctId":"NCT04450212","phase":"NA","title":"Vitamin K Supplementation Study in Healthy Volunteers (Aim 2B)","status":"TERMINATED","sponsor":"University of Washington","startDate":"2017-08-25","conditions":"Vitamin K Status","enrollment":106},{"nctId":"NCT00336232","phase":"NA","title":"Determinants of Vitamin K Metabolism","status":"COMPLETED","sponsor":"Tufts University","startDate":"2006-05","conditions":"Aging, Osteoporosis","enrollment":59},{"nctId":"NCT05713045","phase":"","title":"Late Vitamin K Deficiency-related Bleeding in Neonates (VKLB): Comparison of Different Strategies to Prophylaxis","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria di Parma","startDate":"2020-03-27","conditions":"Late Vitamin K Deficiency-related Bleeding","enrollment":80},{"nctId":"NCT05273775","phase":"PHASE1","title":"A Pharmacokinetic Study to Evaluate the Drug Interaction Between HRS5091 and Probe Drugs in Healthy Volunteers","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-04-29","conditions":"Chronic Hepatitis B","enrollment":22},{"nctId":"NCT05392127","phase":"PHASE1","title":"A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-07-15","conditions":"Rheumatoid Arthritis","enrollment":24},{"nctId":"NCT03878381","phase":"EARLY_PHASE1","title":"Investigating the Wrinkle Reduction Potential of a Novel Compounded Skin Care Cream","status":"COMPLETED","sponsor":"Wayne State University","startDate":"2019-04-01","conditions":"Skin Care","enrollment":10},{"nctId":"NCT05360342","phase":"NA","title":"Incorporation of Vitamin K Into Uremic Lipoproteins","status":"COMPLETED","sponsor":"RWTH Aachen University","startDate":"2020-03-31","conditions":"Vitamin K Deficiency","enrollment":20},{"nctId":"NCT05060809","phase":"PHASE4","title":"Vitamin k1 and Its Relation to Vascular Calcification in Hemodialysis Patients","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-01-01","conditions":"Vascular Calcification","enrollment":120},{"nctId":"NCT03926156","phase":"PHASE3","title":"RIvoraxaban in Mitral Stenosis","status":"TERMINATED","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2019-05-22","conditions":"Mitral Stenosis, Rheumatic Heart Disease, Atrial Fibrillation","enrollment":40},{"nctId":"NCT04477811","phase":"PHASE2, PHASE3","title":"Comparative Study Evaluating the Effect of Vitamin K1 Versus Vitamin K2 on Vascular Calcification in Dialysis Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2020-07-25","conditions":"End Stage Renal Disease on Dialysis","enrollment":40},{"nctId":"NCT01528800","phase":"PHASE2","title":"Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients","status":"COMPLETED","sponsor":"Dr. Rachel Holden","startDate":"2012-11","conditions":"End-stage Kidney Disease","enrollment":85},{"nctId":"NCT01345526","phase":"PHASE2","title":"Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream","status":"COMPLETED","sponsor":"Universitätsmedizin Mannheim","startDate":"2011-04","conditions":"Metastatic Colorectal Cancer","enrollment":124},{"nctId":"NCT03782025","phase":"","title":"Effect of Vitamin K in Critically Ill Patients","status":"COMPLETED","sponsor":"Region Skane","startDate":"2019-02-13","conditions":"Coagulation Factor Deficiency, Coagulopathy, Consumption, Vitamin K Deficiency","enrollment":52},{"nctId":"NCT01742273","phase":"PHASE3","title":"Vitamin K1 to Slow Progression of Vascular Calcification in HD Patients","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2013-10","conditions":"Cardiovascular Diseases","enrollment":63},{"nctId":"NCT01232647","phase":"PHASE2, PHASE3","title":"Vitamin K as Additive Treatment in Osteoporosis","status":"UNKNOWN","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2015-04","conditions":"Post-menopausal Osteoporosis","enrollment":105},{"nctId":"NCT04247087","phase":"NA","title":"Effects of Fhytomenadione on Coronary Artery Calcification of Hemodialysis Patients","status":"COMPLETED","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2017-09-07","conditions":"Coronary Calcification","enrollment":60},{"nctId":"NCT02259647","phase":"NA","title":"Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2014-10-01","conditions":"Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT02278692","phase":"NA","title":"Evaluation of Vitamin K Supplementation for Calcific Uremic Arteriolopathy","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2015-03","conditions":"Calciphylaxis, Calcific Uremic Arteriolopathy","enrollment":26},{"nctId":"NCT03547895","phase":"NA","title":"Management of Decompensated HCV Cirrhotic Patients","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2015-06-01","conditions":"Decompensated Cirrhosis","enrollment":80},{"nctId":"NCT01881204","phase":"NA","title":"Hesperidin and Bone Health in Postmenopausal Women","status":"COMPLETED","sponsor":"Purdue University","startDate":"2011-04","conditions":"Osteoporosis, Postmenopausal","enrollment":12},{"nctId":"NCT02324686","phase":"PHASE2","title":"Vitamin K Supplementation in Patients on Hemodialysis","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2014-01","conditions":"End Stage Renal Failure on Dialysis, Atrial Fibrillation","enrollment":3},{"nctId":"NCT03388970","phase":"EARLY_PHASE1","title":"Vitamin K1 in the Treatment of Spontaneous Intracerebral Hemorrhage","status":"UNKNOWN","sponsor":"HUANG XIANJIAN","startDate":"2017-08-01","conditions":"Intracerebral Haemorrhage in Cerebellum","enrollment":400},{"nctId":"NCT02565836","phase":"","title":"Fixed-dose Activated Versus Variable-dose Inactivated Prothrombin Complex Concentrate for Warfarin-associated Major Bleed","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2015-10","conditions":"Hemorrhage","enrollment":342},{"nctId":"NCT00785109","phase":"PHASE3","title":"Vitamin K Supplement for Inhibition of the Progress in Aortic Valve Calcification","status":"COMPLETED","sponsor":"RWTH Aachen University","startDate":"2010-01","conditions":"Aortic Valve Calcification","enrollment":99},{"nctId":"NCT01474460","phase":"NA","title":"Use of Phytonadione to Reduce International Normalized Ratio (INR) Variability in Patients on Long-term Warfarin Therapy","status":"COMPLETED","sponsor":"James A. Haley Veterans Administration Hospital","startDate":"2011-09","conditions":"Coagulation Delay","enrollment":370},{"nctId":"NCT02867488","phase":"NA","title":"Dose-response Effects of Soybean Oil in Salad Dressing on Carotenoid/Fat-soluble Vitamin Bioavailability in Salad Vegetables","status":"COMPLETED","sponsor":"Iowa State University","startDate":"2009-04","conditions":"Biological Availability","enrollment":""},{"nctId":"NCT00062595","phase":"PHASE3","title":"Vitamin K and Bone Turnover in Postmenopausal Women","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2000-09","conditions":"Osteoporosis","enrollment":375},{"nctId":"NCT02596282","phase":"PHASE2, PHASE3","title":"Enhanced Provision of Male Circumcision (MC) for HIV Prevention, Rakai, Uganda","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2014-10","conditions":"Neonatal Male Circumcision","enrollment":501},{"nctId":"NCT00905229","phase":"NA","title":"Comparing Different Routes and Doses of Phytonadione (Vitamin K) for Reversing Warfarin Treated Patients With Hip Fracture Before Surgery","status":"WITHDRAWN","sponsor":"HaEmek Medical Center, Israel","startDate":"2009-05","conditions":"Bleeding, Complications","enrollment":""},{"nctId":"NCT00990158","phase":"PHASE3","title":"Does Low Dose Oral Vitamin K Improve International Normalized Ratio (INR) Stability?","status":"COMPLETED","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2010-07","conditions":"Coagulation, Bleeding, Thrombosis","enrollment":235},{"nctId":"NCT01507051","phase":"PHASE1","title":"Switching Study From Warfarin to Rivaroxaban","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-11","conditions":"Venous Thrombosis","enrollment":96},{"nctId":"NCT02256813","phase":"PHASE1","title":"Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Warfarin, Omeprazole, Caffeine, and Dextromethorphan in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-09","conditions":"Healthy","enrollment":20},{"nctId":"NCT02250079","phase":"PHASE3","title":"Polyethylene Body Bags as an Alternative to Radiant Heat Lamp During the Neonatal Adaptation in Infants Older Than 29 Weeks","status":"COMPLETED","sponsor":"Universidad Nacional de Colombia","startDate":"2013-06","conditions":"Neonatal Adaptation","enrollment":100},{"nctId":"NCT01533441","phase":"PHASE2","title":"Vitamin K2 Intervention in Patients With Vitamin K Antagonists","status":"COMPLETED","sponsor":"Danisco","startDate":"2012-02","conditions":"Thrombosis","enrollment":50},{"nctId":"NCT01315990","phase":"PHASE4","title":"FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema","status":"UNKNOWN","sponsor":"Dr. Carl Schimanski","startDate":"2011-01","conditions":"Colorectal Cancer Metastatic","enrollment":165},{"nctId":"NCT01111864","phase":"NA","title":"Changes in Microbiota and Iron Status After Iron Fortification of Complementary Foods","status":"COMPLETED","sponsor":"Swiss Federal Institute of Technology","startDate":"2010-02","conditions":"Bacterial Infections","enrollment":160},{"nctId":"NCT01738776","phase":"","title":"Nutritional Risk Factors for Hip Fracture: a Case Control Study","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2009-09","conditions":"Hip Fracture","enrollment":184},{"nctId":"NCT01638182","phase":"NA","title":"Biocomparison Study","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2011-03","conditions":"Bone Health, Vascular Health","enrollment":81},{"nctId":"NCT00995917","phase":"NA","title":"A Pilot Study of Acupoint Injection for Primary Dysmenorrhea","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-10","conditions":"Dysmenorrhea, Pain, Menstrual","enrollment":18},{"nctId":"NCT00794755","phase":"PHASE3","title":"Low Dose Supplementation to Improve Anticoagulation Control With Oral Vitamin K as an Adjuvant to Warfarin Therapy","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2008-11","conditions":"Coagulation","enrollment":100},{"nctId":"NCT00143715","phase":"PHASE3","title":"Oral Vitamin K for Warfarin Associated Coagulopathy","status":"COMPLETED","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2004-09","conditions":"Coagulation, Bleeding, Thrombosis","enrollment":690},{"nctId":"NCT00931437","phase":"NA","title":"Vitamin K-absorption From Dairy","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2009-04","conditions":"Healthy","enrollment":12},{"nctId":"NCT01235325","phase":"PHASE4","title":"The Effect of Vitamin K Supplementation on Bone Health in Adult Crohn's Disease Patients","status":"COMPLETED","sponsor":"University College Cork","startDate":"2008-07","conditions":"Supplementation, Bone Health, Crohn's Disease","enrollment":70},{"nctId":"NCT01194778","phase":"NA","title":"Comparison of Efficacy of Different Dosages Vitamin K2","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2009-10","conditions":"Carboxylation Level, Vitamin K-dependent Proteins","enrollment":82},{"nctId":"NCT01034124","phase":"NA","title":"Mechanisms Underlying Drug-Diet Interactions","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2007-01","conditions":"Pharmacokinetics","enrollment":19},{"nctId":"NCT00698984","phase":"NA","title":"Investigation of the Effect of BONISTEIN(R) Bone Blend on Bone Mineral Density/Content and Biomarkers of Bone Health","status":"COMPLETED","sponsor":"dsm-firmenich Switzerland AG","startDate":"2007-01","conditions":"Osteoporosis","enrollment":70}],"_emaApprovals":[],"_faersSignals":[{"count":316,"reaction":"SEPSIS"},{"count":300,"reaction":"NAUSEA"},{"count":294,"reaction":"VOMITING"},{"count":289,"reaction":"OFF LABEL USE"},{"count":275,"reaction":"ABDOMINAL DISTENSION"},{"count":262,"reaction":"ABDOMINAL PAIN"},{"count":260,"reaction":"ASCITES"},{"count":259,"reaction":"GENERAL PHYSICAL HEALTH DETERIORATION"},{"count":251,"reaction":"HYPONATRAEMIA"},{"count":241,"reaction":"MULTIPLE ORGAN DYSFUNCTION SYNDROME"}],"genericFilers":[{"notes":"","market":"","status":"","company":"","filedDate":"","expectedLaunch":"","applicationNumber":""}],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"💉","route":"Intramuscular","frequency":"As needed","formulation":"injectable emulsion"},"crossReferences":{"chemblId":"CHEMBL1550"},"formularyStatus":[],"_approvalHistory":[{"date":"20260313","type":"ORIG","sponsor":"ORBICULAR","applicationNumber":"ANDA216298"},{"date":"19870805","type":"SUPPL","sponsor":"INTL MEDICATION","applicationNumber":"ANDA083722"},{"date":"20000711","type":"SUPPL","sponsor":"INTL MEDICATION","applicationNumber":"ANDA083722"},{"date":"20231023","type":"SUPPL","sponsor":"INTL MEDICATION","applicationNumber":"ANDA083722"},{"date":"19941110","type":"SUPPL","sponsor":"INTL MEDICATION","applicationNumber":"ANDA083722"},{"date":"19940617","type":"SUPPL","sponsor":"INTL MEDICATION","applicationNumber":"ANDA083722"},{"date":"19940203","type":"SUPPL","sponsor":"INTL MEDICATION","applicationNumber":"ANDA083722"},{"date":"19760301","type":"ORIG","sponsor":"INTL MEDICATION","applicationNumber":"ANDA083722"},{"date":"20010104","type":"SUPPL","sponsor":"INTL MEDICATION","applicationNumber":"ANDA083722"},{"date":"19930830","type":"SUPPL","sponsor":"INTL MEDICATION","applicationNumber":"ANDA083722"},{"date":"20231023","type":"SUPPL","sponsor":"INTL MEDICATION","applicationNumber":"ANDA083722"},{"date":"19950919","type":"SUPPL","sponsor":"INTL MEDICATION","applicationNumber":"ANDA083722"},{"date":"20231023","type":"SUPPL","sponsor":"INTL MEDICATION","applicationNumber":"ANDA083722"},{"date":"20030418","type":"SUPPL","sponsor":"INTL MEDICATION","applicationNumber":"ANDA083722"},{"date":"19980114","type":"SUPPL","sponsor":"INTL MEDICATION","applicationNumber":"ANDA083722"},{"date":"20020306","type":"SUPPL","sponsor":"INTL MEDICATION","applicationNumber":"ANDA083722"},{"date":"19931029","type":"SUPPL","sponsor":"INTL MEDICATION","applicationNumber":"ANDA083722"},{"date":"19921209","type":"SUPPL","sponsor":"INTL MEDICATION","applicationNumber":"ANDA083722"},{"date":"20220422","type":"ORIG","sponsor":"CIPLA","applicationNumber":"ANDA214596"},{"date":"20190220","type":"ORIG","sponsor":"ZYDUS LIFESCIENCES","applicationNumber":"ANDA210189"},{"date":"20190522","type":"ORIG","sponsor":"DR REDDYS","applicationNumber":"ANDA207719"}],"developmentCodes":[],"ownershipHistory":[{"notes":"","period":"","companyName":"","relationship":""}],"publicationCount":216,"therapeuticAreas":["Oncology"],"trialPhaseCounts":{"":5,"NA":17,"PHASE1":4,"PHASE2":6,"PHASE3":9,"PHASE4":3,"EARLY_PHASE1":2,"PHASE1, PHASE2":1,"PHASE2, PHASE3":3},"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"approved","brandName":"PHYTONADIONE","genericName":"PHYTONADIONE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1982","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1992-12-09T00:00:00.000Z","mah":"INTL MEDICATION","brand_name_local":null,"application_number":"ANDA083722"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-02-20T00:00:00.000Z","mah":"ZYDUS LIFESCIENCES","brand_name_local":null,"application_number":"ANDA210189"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-07-28T00:00:00.000Z","mah":"SCIEGEN PHARMS","brand_name_local":null,"application_number":"ANDA213329"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-10-12T00:00:00.000Z","mah":"AGNITIO","brand_name_local":null,"application_number":"ANDA213336"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-01-03T00:00:00.000Z","mah":"CIPLA","brand_name_local":null,"application_number":"ANDA214966"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T03:01:04.217146+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}